Healthcare giant Johnson & Johnson (JNJ) has yet to turn over documents requested by a U.S. government panel investigating recalls and manufacturing problems at the company, a move that might provoke the government to take a firmer stand.

The U.S. House Committee on Oversight and Government Reform, which made the request, is looking into manufacturing problems at the J&J facility in Pennsylvania. The facility made children's medicines.

On April 30, J&J's McNeil Consumer Healthcare unit recalled certain Benadryl, Motrin, Tylenol and Zyrtec pain and cold medicines for children because of manufacturing problems. Among the problems was the potential for metal particles in the products.

Subsequently, other medicines were also found to have problems.

"Johnson & Johnson has not yet complied with the Committee's request for documents," said Jenny Rosenberg, a spokeswoman for the U.S. House Committee on Oversight and Government Reform, which is looking into manufacturing problems and recalls of over-the-counter children's drugs made by J&J. "If necessary to ensure cooperation with the Committee's investigation, further action will be taken."

A phone call to the company was not immediately returned.

In particular, the committee is interested in how J&J handled a recall of pain reliever Motrin in 2008. J&J allegedly hired a contractor to pose as consumers and buy the medicine rather than issue a formal recall.

Shares of Johnson & Johnson were little changed on Monday, at $58.00.

-By Andrew Morse, Dow Jones Newswires; 415-439-6402; andrew.morse@dowjones.com

 
 
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Johnson and Johnson Charts.